A new market report puts what the industry calls the decentralized trials market at $38 billion by 2035, growing more than 14% per year. That’s an impressive number, and it’s going to get cited a lot. For us, though, the most useful takeaway in the report is buried a bit deeper.
Healthcare Foresights singles out hybrid trial models as a major factor in the market growth: keeping complex procedures like diagnostics, imaging, or first-dose administration at a site while telemedicine and wearables handle routine monitoring closer to where the participant is in real life. The report calls this approach “the most practical and scalable route for the future of clinical research.”
We’d put it more plainly: it’s the model our site network was built around, before the industry had a simple way to describe it.
The report frames hybrid trial design as a technology and delivery question: which visits happen where. In our experience, however, the harder question shows up in feasibility, where a site that also runs hybrid and virtual visits doesn’t have a box to check. We built our team to close that gap. One coordinated team, working from a single SOP framework, follows a participant across every setting: a physical site, home visit, telemedicine, and even our mobile research units (MRUs). That means fewer vendors and contracts, and one team that knows how to bring research to the participant.
The market is starting to describe—and validate—what we already do. That’s a useful signal: sponsors are going to start asking for hybrid models by name. The advantage will go to whoever already knows how to run them well.
Want that advantage on your next study? Let’s talk about how hybrid fits your protocol.